Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
54.55
-0.08 (-0.15%)
At close: Dec 5, 2025, 4:00 PM EST
54.53
-0.02 (-0.04%)
After-hours: Dec 5, 2025, 5:40 PM EST
Akero Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Akero Therapeutics stock have an average target of 73.56, with a low estimate of 54 and a high estimate of 109. The average target predicts an increase of 34.85% from the current stock price of 54.55.
Analyst Consensus: Buy
* Price targets were last updated on Oct 10, 2025.
Analyst Ratings
The average analyst rating for Akero Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 5 | 5 | 5 |
| Buy | 3 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 8 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $72 → $54 | Strong Buy → Hold | Downgrades | $72 → $54 | -1.01% | Oct 10, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $75 → $56 | Strong Buy → Hold | Downgrades | $75 → $56 | +2.66% | Oct 9, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $73 → $54 | Strong Buy → Hold | Downgrades | $73 → $54 | -1.01% | Oct 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +31.99% | Sep 4, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.79
from -3.75
EPS Next Year
-4.40
from -3.79
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.77 | -4.18 | ||||
| Avg | -3.79 | -4.40 | ||||
| Low | -3.86 | -4.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.